Table 1. Demographic and clinical characteristics of analyzed patients to follow up (n=70).

	Azithromycin Group n=37	Placebo Group n=33	P
Age at enrollment, months, mean (SD)	3.26 (2.49)	3.14 (2.29)	0.843
Weight at enrollment, kg, mean (SD)	5.72 (1.76)	5.85 (1.50)	0.749
Gender, boys, n (%)	22 (59.5)	21 (63.6)	0.720
Use of β2 agonist, n (%)	9 (24.3)	11 (33.3)	0.405
Hypoxemia at admission, n (%)	37 (100)	33 (100)	1.000
Positive for any virus	20 (54.1)	22 (66.7)	0.288
Positive for RSV, n (%)	17 (45.9)	21 (63.6)	0.182
Duration of hospitalization, days, mean (SD)	5.32 (2.63)	5.85 (3.30)	0.464

SD: Standard Deviation; RSV: respiratory syncicial virus; n: sample size; p-value: significance level (probability of obtaining test results as extreme as the results observed).